Insider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) CEO Sells 94,087 Shares of Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CEO David James Lennon sold 94,087 shares of the company’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $3.43, for a total transaction of $322,718.41. Following the transaction, the chief executive officer directly owned 597,067 shares of the company’s stock, valued at approximately $2,047,939.81. This represents a 13.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David James Lennon also recently made the following trade(s):

• On Wednesday, April 8th, David James Lennon sold 63,945 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.40, for a total transaction of $217,413.00.
• On Monday, April 6th, David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.51, for a total transaction of $359,406.45.
• On Thursday, April 2nd, David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.48, for a total transaction of $93,465.84.
• On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total transaction of $16,881.00.

Whitehawk Therapeutics Trading Down 0.6%

Shares of NASDAQ WHWK traded down $0.02 on Wednesday, reaching $3.41. 212,634 shares of the company traded hands, compared to its average volume of 201,638. Whitehawk Therapeutics, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $4.48. The company has a 50 day moving average of $3.32 and a 200 day moving average of $2.69. The stock has a market capitalization of $160.95 million, a PE ratio of 7.26 and a beta of 0.57.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.21.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. JonesTrading assumed coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Wall Street Zen raised shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Oppenheimer assumed coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an “outperform” rating and a $6.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.50.

Institutional Trading of Whitehawk Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of WHWK. Vanguard Group Inc. acquired a new stake in Whitehawk Therapeutics during the 3rd quarter worth approximately $2,552,000. Peapod Lane Capital LLC acquired a new stake in Whitehawk Therapeutics during the 3rd quarter worth approximately $577,000. Dimensional Fund Advisors LP purchased a new position in Whitehawk Therapeutics in the 3rd quarter worth approximately $84,000. Avoro Capital Advisors LLC purchased a new position in Whitehawk Therapeutics in the 3rd quarter worth approximately $5,414,000. Finally, Suvretta Capital Management LLC purchased a new position in Whitehawk Therapeutics in the 3rd quarter worth approximately $7,030,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.